Literature DB >> 31257407

Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.

Naveen Rathi1, Paul K Whelton2, Glenn M Chertow3, William C Cushman4, Alfred K Cheung1,5, Guo Wei1, Robert Boucher1, Paul L Kimmel6, Adam P Bress7, Holly J Kramer8, Catreena Al-Marji1, Tom Greene9, Srinivasan Beddhu1,5.   

Abstract

BACKGROUND: More than one-third of US adults have prediabetes, which is typically accompanied by hypertension.
METHODS: We examined whether prediabetes modified the effects of intensive systolic blood pressure (SBP) lowering on the incidence of chronic kidney disease (CKD) and acute kidney injury (AKI) events in a post-hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Diabetes was a SPRINT exclusion criterion. We defined normoglycemia and prediabetes as fasting plasma glucose <100 mg/dl and ≥100 mg/dl, respectively.
RESULTS: Of the 9,323 participants included in this analysis, 3,898 (41.8%) had prediabetes and the rest (5,425) had normoglycemia. In participants with baseline estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m2, incident CKD was defined as a ≥30% decline in eGFR to below 60 ml/min/1.73 m2 with repeat confirmation. AKI events were identified clinically. In the non-CKD participants (n = 6,678), there were 164 incident CKD events. The hazard ratios (HRs) for incident CKD for intensive SBP goal (<120 mm Hg) vs. standard SBP goal (<140 mm Hg) in the normoglycemia (HR: 3.25, 95% CI: 2.03, 5.19) and prediabetes (HR: 3.90, 95% CI: 2.17, 7.02) groups were similar (interaction P value 0.64). In the entire analytic cohort (N = 9,323), there were 310 AKI events. AKI HRs for intensive vs. standard SBP in the normoglycemia (HR: 1.59, 95% CI: 1.17, 2.15) and prediabetes (HR: 1.74, 95% CI: 1.22, 2.48) groups were also similar (interaction P value 0.71).
CONCLUSIONS: Prediabetes was highly prevalent, but there was no evidence that prediabetes modified the effects of SPRINT intervention on kidney events.CLINICAL TRIALS REGISTRATIONNCT01206062. © Published by Oxford University Press on behalf of American Journal of Hypertension Ltd 2019.

Entities:  

Keywords:  acute kidney injury; blood pressure; chronic kidney disease; hypertension; prediabetes

Year:  2019        PMID: 31257407      PMCID: PMC6856623          DOI: 10.1093/ajh/hpz105

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  35 in total

1.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

Review 2.  Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials.

Authors:  Sverre E Kjeldsen; Per Lund-Johansen; Peter M Nilsson; Giuseppe Mancia
Journal:  Hypertension       Date:  2016-03-21       Impact factor: 10.190

3.  Prediabetes as a Precursor to Diabetic Kidney Disease.

Authors:  Luca De Nicola; Giuseppe Conte; Roberto Minutolo
Journal:  Am J Kidney Dis       Date:  2016-06       Impact factor: 8.860

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.

Authors:  Chi-yuan Hsu; Charles E McCulloch; Jeanne Darbinian; Alan S Go; Carlos Iribarren
Journal:  Arch Intern Med       Date:  2005-04-25

6.  Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice.

Authors:  Aidar R Gosmanov; Jim Wan
Journal:  Am J Med Sci       Date:  2014-09       Impact factor: 2.378

7.  Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012.

Authors:  Andy Menke; Sarah Casagrande; Linda Geiss; Catherine C Cowie
Journal:  JAMA       Date:  2015-09-08       Impact factor: 56.272

8.  Diabetes mellitus, fasting glucose, and risk of cause-specific death.

Authors:  Alexander Thompson; Emanuele Di Angelantonio; Pei Gao; Nadeem Sarwar; Sreenivasa Rao Kondapally Seshasai; Stephen Kaptoge; Peter H Whincup; Kenneth J Mukamal; Richard F Gillum; Ingar Holme; Inger Njølstad; Astrid Fletcher; Peter Nilsson; Sarah Lewington; Rory Collins; Vilmundur Gudnason; Simon G Thompson; Naveed Sattar; Elizabeth Selvin; Frank B Hu; John Danesh
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

9.  Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Karen C Johnson; Paul K Whelton; William C Cushman; Jeffrey A Cutler; Gregory W Evans; Joni K Snyder; Walter T Ambrosius; Srinivasan Beddhu; Alfred K Cheung; Lawrence J Fine; Cora E Lewis; Mahboob Rahman; David M Reboussin; Michael V Rocco; Suzanne Oparil; Jackson T Wright
Journal:  Hypertension       Date:  2018-03-12       Impact factor: 10.190

10.  Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.

Authors:  Srinivasan Beddhu; Glenn M Chertow; Tom Greene; Paul K Whelton; Walter T Ambrosius; Alfred K Cheung; Jeffrey Cutler; Lawrence Fine; Robert Boucher; Guo Wei; Chong Zhang; Holly Kramer; Adam P Bress; Paul L Kimmel; Suzanne Oparil; Cora E Lewis; Mahboob Rahman; William C Cushman
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

View more
  2 in total

1.  Association of blood pressure and long-term change with chronic kidney disease risk among Chinese adults with different glucose metabolism according to the 2017 ACC/AHA guidelines.

Authors:  Jia He; Zhaoyang Li; Ruixin Wang; Hongli Nie; Fei Wang; Jing Yuan; Xiaoping Miao; Ping Yao; Sheng Wei; Xiaomin Zhang; Huan Guo; Handong Yang; Tangchun Wu; Meian He
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-11-12       Impact factor: 3.738

2.  Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; Muhammad Shahzeb Khan; Nikolaus Marx; Carolyn S P Lam; Sven Schnaidt; Anne Pernille Ofstad; Martina Brueckmann; Waheed Jamal; Edimar A Bocchi; Piotr Ponikowski; Sergio V Perrone; James L Januzzi; Subodh Verma; Michael Böhm; João Pedro Ferreira; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  Circulation       Date:  2020-11-11       Impact factor: 29.690

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.